Completed PHASE2 INTERVENTIONAL 1-arm NCT01297244

A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Sponsor: AVEO Pharmaceuticals, Inc.

Interventions Tivozanib

Updated 8 times since 2017 Last updated: Oct 5, 2020 Started: Jan 31, 2011 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01297244, this PHASE2 trial focuses on Renal Cell Carcinoma and remains completed. Sponsored by AVEO Pharmaceuticals, Inc., it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AVEO Pharmaceuticals, Inc.

Data source: AVEO Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Baton Rouge, United States , Beech Grove, United States , Boston, United States , Burbank, United States , Chapel Hill, United States , Columbus, United States , Corpus Christi, United States , Dallas, United States , Denver, United States and 14 more locations